Clinical trials: Acute Lymphoblastic Leukemia ALL
Acute Lymphoblastic Leukemia
Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat B-cell Acute Lymphoblastic Leukemia(B-ALL)
This is an open-label, multicentre study to characterize the safety and preliminary efficacy of the human anti CD19 antibody MOR00208 in adult subjects with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL)
- Trial name
- NCT01685021
- Testing
- MOR00208 (formerly Xmab5574)
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- MorphoSys AG
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer
RATIONALE: Growth factors, such as palifermin, may prevent chronic graft-versus-host disease caused by donor stem cell transplant.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT01233921
- Testing
- palifermin, flow cytometry, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Martin, Paul
Cytokine Release Syndrome, ICANS
Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy
This study will evaluate the use of siltuximab to decrease the severity of cytokine release syndrome (CRS) and immune effector cell-associated neurological syndrome (ICANS) in patients who will receive chimeric antigen receptor…
- Conditions
- Cytokine Release Syndrome, ICANS, Lymphoma, Non-Hodgkin, Multiple Myeloma
- Trial name
- NCT04975555
- Testing
- Siltuximab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Alabama at Birmingham
Myeloid Leukemia, Lymphoblastic Leukemia
Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor
The purpose of this study is to determine whether the administration of a donor lymphocyte preparation depleted of functional host alloreactive T-cells (ATIR) after a T-cell depleted stem cell transplant from a related…
- Conditions
- Myeloid Leukemia, Lymphoblastic Leukemia, Lymphoma, Multiple Myeloma
- Trial name
- NCT00967343
- Testing
- Donor lymphocyte preparation depleted of host functional alloreactive T-cells
- Where
- 15 sites in United States, Belgium and 5 more
- Volunteers
- 40 people
- Sponsor
- Kiadis Pharma
Acute Lymphoblastic Leukemia, Precursor B-Cell Lymphoblastic Leukemia
A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL
This is a pilot study using decitabine and vorinostat before and during chemotherapy with vincristine, dexamethasone, mitoxantrone, and peg-asparaginase in pediatric patients with acute lymphoblastic leukemia (ALL).
- Conditions
- Acute Lymphoblastic Leukemia, Precursor B-Cell Lymphoblastic Leukemia, Precursor T-Cell Lymphoblastic Leukemia
- Trial name
- NCT01483690
- Testing
- Decitabine, Vorinostat, Vincristine
- Where
- 28 sites in United States, Australia
- Volunteers
- 23 people
- Sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
Blastic Phase, Childhood Acute Promyelocytic Leukemia With PML-RARA
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
This phase I/II trial is studying the side effects and best dose of sorafenib in treating young patients with relapsed or refractory solid tumors or leukemia.
- Conditions
- Blastic Phase, Childhood Acute Promyelocytic Leukemia With PML-RARA, Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Childhood Solid Neoplasm
- Trial name
- NCT01445080
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Sorafenib Tosylate
- Where
- 25 sites in United States, Canada
- Volunteers
- 70 people
- Sponsor
- National Cancer Institute (NCI)
Precursor Cell Lymphoblastic Leukemia-Lymphoma
InO - A Retrospective Study of UK Patients With Leukaemia
The purpose of this study is to describe the demographics and clinical characteristics, treatment pathway, and effectiveness and safety of inotuzumab ozogamicin in patients with relapsed/refractory B-cell acute lymphoblastic…
- Trial name
- InO (NCT04456959)
- Testing
- Inotuzumab Ozogamicin
- Where
- 4 sites in United Kingdom
- Volunteers
- 28 people
- Sponsor
- Pfizer
Myeloproliferative Disorders, Leukemia
Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy before a donor umbilical cord blood transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00827099
- Testing
- anti-thymocyte globulin, fludarabine phosphate, Melphalan
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Northside Hospital, Inc.
Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL)
IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT
This is a multi-center, phase I/II clinical trial for patients who have relapsed more than 60 day after allogeneic transplant for a hematologic malignancy. The study consists of two phases.
- Conditions
- Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Myelodysplastic Syndromes (MDS), Lymphoma
- Trial name
- NCT01885897
- Testing
- ALT-803
- Where
- 3 sites in United States
- Volunteers
- 33 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission
Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant
This randomized phase III trial is studying how well Caphosol rinse works in preventing mucositis in young patients undergoing autologous or donor stem cell transplant.
- Conditions
- Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes
- Trial name
- NCT01305200
- Testing
- supersaturated calcium phosphate rinse, questionnaire administration, quality-of-life assessment
- Where
- 35 sites in United States, Australia and 1 more
- Volunteers
- 226 people
- Sponsor
- Children's Oncology Group
Chronic Myeloproliferative Disorders, Fatigue
American Ginseng in Treating Patients With Fatigue Caused by Cancer
RATIONALE: American ginseng may reduce fatigue in patients with cancer. It is not yet known whether American ginseng is more effective than a placebo in treating cancer-related fatigue.
- Conditions
- Chronic Myeloproliferative Disorders, Fatigue, Leukemia, Lymphoma
- Trial name
- NCT00719563
- Testing
- American ginseng
- Where
- 326 sites in United States
- Volunteers
- 364 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Chronic Myelogenous Leukemia, Acute Myelogenous Leukemia
Relapsed Malignant Blood Cancer After Allogeneic Hematopoietic Stem Cell Transplantation
Background: Allogeneic hematopoietic stem cell transplantation (or allotransplant; donor blood stem cells) have been used with varying degrees of success as an immune therapy for blood-system cancers (leukemias, myelodysplastic…
- Conditions
- Chronic Myelogenous Leukemia, Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Hodgkins Lymphoma
- Trial name
- NCT01326728
- Testing
- Allogeneic stem cell transplant
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
B Acute Lymphoblastic Leukemia, Minimal Residual Disease
Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia
This phase II trial studies how well pembrolizumab works in treating small amounts of cancer cells that remain after attempts to remove the cancer has been made in patients with acute lymphoblastic leukemia.
- Conditions
- B Acute Lymphoblastic Leukemia, Minimal Residual Disease, Recurrent Acute Lymphoblastic Leukemia, T Acute Lymphoblastic Leukemia
- Trial name
- NCT02767934
- Testing
- Laboratory Biomarker Analysis, Pembrolizumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Washington
Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
This phase II/III trial is studying the side effects and how well giving dasatinib together with combination chemotherapy works in treating young patients with newly diagnosed acute lymphoblastic leukemia (ALL).
- Conditions
- Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
- Trial name
- NCT00720109
- Testing
- Asparaginase, Cyclophosphamide, Cytarabine
- Where
- 134 sites in United States, Australia and 3 more
- Volunteers
- 63 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Myeloid Leukemia (CML), Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)
The purpose of this study is to assess the safety and efficacy of ponatinib in Japanese patients with chronic myeloid leukemia (CML) who have experienced failure of dasatinib or nilotinib or with Ph+ acute lymphoblastic leukemia…
- Trial name
- NCT01667133
- Testing
- ponatinib - Phase 1, ponatinib - Phase 2
- Where
- 11 sites in Japan
- Volunteers
- 35 people
- Sponsor
- Ariad Pharmaceuticals
B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1, Recurrent Adult Acute Lymphoblastic Leukemia
Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
The purpose of this research study is to determine the acceptable upper limit dose of nivolumab in combination with dasatinib that may be given to patients with relapsed/refractory philadelphia chromosome positive acute…
- Conditions
- B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Refractory Adult Acute Lymphoblastic Leukemia
- Trial name
- NCT02819804
- Testing
- Dasatinib, Laboratory Biomarker Analysis, Nivolumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Northwestern University
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
RATIONALE: Giving chemotherapy and total-body irradiation (TBI) before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells and helps stop the patient's immune system from rejecting the donor's stem…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT01076270
- Testing
- plerixafor, filgrastim, peripheral blood stem cell transplantation
- Where
- United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Fred Hutchinson Cancer Center
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Study of Immune Response Modifier in the Treatment of Hematologic Malignancies
The purpose of this study is to evaluate the anti-tumor activity of 852A when used to treat certain hematologic malignancies not responding to standard treatment.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma
- Trial name
- NCT00276159
- Testing
- 852A
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Acute Lymphoblastic Leukemia
Phase II Study of the BiTE® Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)
The purpose of this study is to determine whether the bispecific T-cell engager (BiTE®) Blinatumomab (MT103) is effective in the treatment of ALL patients with minimal residual disease.
- Trial name
- NCT00560794
- Testing
- Blinatumomab (MT103)
- Where
- 6 sites in Germany
- Volunteers
- 21 people
- Sponsor
- Amgen Research (Munich) GmbH
Acute Lymphoblastic Leukemia, Leukemia, Acute Myeloid (AML), Child
Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant
This study will evaluate pediatric patients with malignant or non-malignant blood cell disorders who are having a blood stem cell transplant depleted of T cell receptor (TCR) alfa and beta cells that comes from a partially…
- Conditions
- Acute Lymphoblastic Leukemia, Leukemia, Acute Myeloid (AML), Child, Lymphoma, Non-Hodgkin, Myelodysplastic Syndrome
- Trial name
- NCT02065869
- Testing
- BPX-501 T cells, Rimiducid
- Where
- 4 sites in Italy, United Kingdom
- Volunteers
- 187 people
- Sponsor
- Bellicum Pharmaceuticals